Loading
Pharmaceutical
9 min read
Areas of Expertise :
Finance, Accounting, Corporate Governance, Economic Damages, Securities
Published Date:
Last Modified Date:
Jurisdiction:
Federal. Third Circuit
In re Valeant Pharmaceuticals International, Inc. Securities Litigation is a consolidated class action in the U.S. District Court for the District of New Jersey (Master No. 3:15-cv-07658-MAS-LHG) covering investors who bought Valeant securities between January 4, 2013, and March 15, 2016. The consolidated complaint alleges that investors were misled about Valeant’s business model and finances, including the company’s undisclosed control of a specialty-pharmacy network (Philidor), steep drug-price increases, practices such as altering prescriptions or waiving copays, and revenue recognition that counted shipments into the captive network, followed by later corrections and admissions about internal-control weaknesses. In plain terms, the filings claim Valeant painted a healthier picture of sales and operations than what existed, and when details emerged, the company revised its results and acknowledged control issues.
The litigation culminated in a $1.21 billion settlement announced December 16, 2019, and granted final approval on January 31, 2021; Valeant (now Bausch Health Companies Inc.) admitted no liability and denied all allegations of wrongdoing, and several related investor “opt-out” suits continued alongside the class resolution. A Third Circuit decision, Aly v. Valeant (June 16, 2021), held that American Pipe tolling applied to certain investors who filed individual actions before class certification, illustrating how the case also shaped modern securities litigation procedure. Put simply, the appellate ruling explained that some investors did not lose their time to sue while the class case was pending.
The consolidated complaint defines a class period starting January 4, 2013, during which investors allege they were misled about Valeant’s business model, pharmacy relationships, pricing practices, and revenue recognition. In plain terms, the filings claim Valeant painted a stronger picture of sales and operations than reality, later acknowledging internal-control weaknesses and correcting financials.
Plaintiffs allege false or misleading statements in offering materials used for Valeant’s March 2015 stock sale, forming the basis for Section 11 and 12(a)(2) counts tied to that offering. This offering is one of several transactions the complaint places at the center of alleged misstatements and omissions.
An initial putative class action was filed in the District of New Jersey following public scrutiny of Valeant’s practices. This filing ultimately became the nucleus of the consolidated case captioned In re Valeant Pharmaceuticals International, Inc. Securities Litigation.
According to the complaint, after reports on Philidor’s practices, major pharmacy benefit managers said on October 29 that they would no longer reimburse Philidor, and on October 30 Valeant announced it was ending the relationship, prompting Philidor’s closure. This episode is described as a key turning point that surfaced hidden pharmacy ties and billing tactics.
Valeant announced it would restate its financial results for 2014 and the first three quarters of 2015 due to Philidor-related accounting. This disclosure signaled that earlier reports were inaccurate and heightened investor concerns about revenue recognition and internal controls.
Valeant released unaudited fourth-quarter 2015 results and sharply reduced its 2016 revenue and earnings guidance, citing the fallout from Philidor’s closure and other business adjustments. The company acknowledged significant financial impacts, and the disclosures prompted a steep stock drop.
Valeant filed an 8-K with the SEC formally stating that previously issued financial statements for 2014 and the first three quarters of 2015 should no longer be relied upon. This official non-reliance notice reinforced the scope of the restatement.
The court consolidated related actions under Master No. 3:15-cv-07658-MAS-LHG and appointed TIAA as Lead Plaintiff and Robbins Geller as Lead Counsel, formalizing the structure for the case to proceed. This order set the stage for unified pleadings and discovery.
Plaintiffs filed an extensive consolidated complaint detailing allegations about a hidden specialty-pharmacy network (Philidor), steep price increases, altered prescriptions, waived copays, and revenue booked on shipments into the captive channel. The complaint also alleges later restatements and acknowledges internal-control weaknesses.
Plaintiffs filed an amended consolidated complaint, which the settlement site notes added insider trading claims against certain defendants while continuing Exchange Act and Securities Act theories. The case continued through heavy discovery and motion practice.
The court referred the litigation to Special Master Hon. Dennis M. Cavanaugh, U.S.D.J. (Ret.), who oversaw settlement discussions and provided procedural recommendations. This referral is noted in the settlement administrator’s overview.
The parties signed a stipulation of settlement on December 15, 2019, and the next day, December 16, 2019, the $1.21 billion settlement was publicly announced. The agreement set out the release, class definitions, and payment mechanics.
The Special Master issued a Report and Recommendation granting the motions for final approval and plan of allocation, and for awards consistent with the Private Securities Litigation Reform Act. This was a key procedural step toward closing the class action.
The District of New Jersey granted final approval of the $1.21 billion settlement, resolving and discharging class claims; certain opt-out actions remained ongoing separately. This order marked the final resolution of the class case and authorized distribution consistent with the agreement.
In Aly v. Valeant, the Third Circuit held that American Pipe tolling applied even where individual opt-out complaints were filed before a class-certification ruling, a point relevant to investors choosing between class participation and separate suits. (Note: while the certified class period was January 4, 2013–March 15, 2016, the Aly appeal involved a narrower “Relevant Period” of February 23–October 20, 2015 for those opt-out plaintiffs.) This appellate outcome illustrates the case’s procedural impact alongside the settlement.
Court:
United States District Court for the District of New Jersey
Case Name:
In re Valeant Pharmaceuticals International, Inc. Securities Litigation
Securities Litigation
Securities Class Action
Securities Fraud
Accounting Fraud
Financial Reporting
Internal Controls
Underwriting
Investment Fraud
Generally Accepted Accounting Principles GAAP
In re Valeant Pharmaceuticals International, Inc. Securities Litigation is a consolidated class action in the U.S. District Court for the District of New Jersey (Master No. 3:15-cv-07658-MAS-LHG) covering investors who bought Valeant securities between January 4, 2013, and March 15, 2016. The consolidated complaint alleges that investors were misled about Valeant’s business model and finances, including the company’s undisclosed control of a specialty-pharmacy network (Philidor), steep drug-price increases, practices such as altering prescriptions or waiving copays, and revenue recognition that counted shipments into the captive network, followed by later corrections and admissions about internal-control weaknesses. In plain terms, the filings claim Valeant painted a healthier picture of sales and operations than what existed, and when details emerged, the company revised its results and acknowledged control issues.
The litigation culminated in a $1.21 billion settlement announced December 16, 2019, and granted final approval on January 31, 2021; Valeant (now Bausch Health Companies Inc.) admitted no liability and denied all allegations of wrongdoing, and several related investor “opt-out” suits continued alongside the class resolution. A Third Circuit decision, Aly v. Valeant (June 16, 2021), held that American Pipe tolling applied to certain investors who filed individual actions before class certification, illustrating how the case also shaped modern securities litigation procedure. Put simply, the appellate ruling explained that some investors did not lose their time to sue while the class case was pending.
The consolidated complaint defines a class period starting January 4, 2013, during which investors allege they were misled about Valeant’s business model, pharmacy relationships, pricing practices, and revenue recognition. In plain terms, the filings claim Valeant painted a stronger picture of sales and operations than reality, later acknowledging internal-control weaknesses and correcting financials.
Plaintiffs allege false or misleading statements in offering materials used for Valeant’s March 2015 stock sale, forming the basis for Section 11 and 12(a)(2) counts tied to that offering. This offering is one of several transactions the complaint places at the center of alleged misstatements and omissions.
An initial putative class action was filed in the District of New Jersey following public scrutiny of Valeant’s practices. This filing ultimately became the nucleus of the consolidated case captioned In re Valeant Pharmaceuticals International, Inc. Securities Litigation.
According to the complaint, after reports on Philidor’s practices, major pharmacy benefit managers said on October 29 that they would no longer reimburse Philidor, and on October 30 Valeant announced it was ending the relationship, prompting Philidor’s closure. This episode is described as a key turning point that surfaced hidden pharmacy ties and billing tactics.
Valeant announced it would restate its financial results for 2014 and the first three quarters of 2015 due to Philidor-related accounting. This disclosure signaled that earlier reports were inaccurate and heightened investor concerns about revenue recognition and internal controls.
Valeant released unaudited fourth-quarter 2015 results and sharply reduced its 2016 revenue and earnings guidance, citing the fallout from Philidor’s closure and other business adjustments. The company acknowledged significant financial impacts, and the disclosures prompted a steep stock drop.
Valeant filed an 8-K with the SEC formally stating that previously issued financial statements for 2014 and the first three quarters of 2015 should no longer be relied upon. This official non-reliance notice reinforced the scope of the restatement.
The court consolidated related actions under Master No. 3:15-cv-07658-MAS-LHG and appointed TIAA as Lead Plaintiff and Robbins Geller as Lead Counsel, formalizing the structure for the case to proceed. This order set the stage for unified pleadings and discovery.
Plaintiffs filed an extensive consolidated complaint detailing allegations about a hidden specialty-pharmacy network (Philidor), steep price increases, altered prescriptions, waived copays, and revenue booked on shipments into the captive channel. The complaint also alleges later restatements and acknowledges internal-control weaknesses.
Plaintiffs filed an amended consolidated complaint, which the settlement site notes added insider trading claims against certain defendants while continuing Exchange Act and Securities Act theories. The case continued through heavy discovery and motion practice.
The court referred the litigation to Special Master Hon. Dennis M. Cavanaugh, U.S.D.J. (Ret.), who oversaw settlement discussions and provided procedural recommendations. This referral is noted in the settlement administrator’s overview.
The parties signed a stipulation of settlement on December 15, 2019, and the next day, December 16, 2019, the $1.21 billion settlement was publicly announced. The agreement set out the release, class definitions, and payment mechanics.
The Special Master issued a Report and Recommendation granting the motions for final approval and plan of allocation, and for awards consistent with the Private Securities Litigation Reform Act. This was a key procedural step toward closing the class action.
The District of New Jersey granted final approval of the $1.21 billion settlement, resolving and discharging class claims; certain opt-out actions remained ongoing separately. This order marked the final resolution of the class case and authorized distribution consistent with the agreement.
In Aly v. Valeant, the Third Circuit held that American Pipe tolling applied even where individual opt-out complaints were filed before a class-certification ruling, a point relevant to investors choosing between class participation and separate suits. (Note: while the certified class period was January 4, 2013–March 15, 2016, the Aly appeal involved a narrower “Relevant Period” of February 23–October 20, 2015 for those opt-out plaintiffs.) This appellate outcome illustrates the case’s procedural impact alongside the settlement.
Securities Litigation Expert Witness
Securities litigation experts are often engaged to analyze alleged market misstatements, explain reliance, and link corrective disclosures to investor losses in securities class actions. In these cases, testimony typically addresses stock-price impact and class-wide damages during the alleged class period. They are generally called in to clarify how disclosures and omissions shaped investor harm.
Accounting Expert Witness
Accounting expert witnesses are often engaged to review financial statements, evaluate GAAP compliance, and assess internal-control disclosures in securities cases. These experts are generally called in to clarify accounting practices, audit responsibilities, and how reporting issues affected investors.
Corporate Governance Expert Witness
Corporate governance experts are often consulted to assess directors’ and officers’ oversight duties, especially when registration statements and public filings are at issue. The Valeant case included allegations involving director sign-offs on the March 2015 stock offering and oversight of disclosure practices. These experts are generally called in to clarify board responsibilities in maintaining accurate corporate reporting.
Economic Damages Expert Witness
Economic Damages experts are often engaged to conduct event studies, measure stock-price inflation, and calculate investor losses tied to corrective disclosures. In such cases, stock value fell dramatically following revelations about Philidor, drug pricing, and restatements, culminating in a $1.21 billion settlement. These experts are generally called in to provide models linking disclosure events to class-wide damages.
Underwriting Expert Witness
Underwriting experts are often engaged to explain securities offering standards, due-diligence practices, and the responsibilities of banks in preparing registration statements. These experts are generally called in to describe industry practices for evaluating disclosures and compliance with federal securities laws.
Disclosure Controls for Complex Distribution Models
The consolidated complaint alleges Valeant failed to transparently disclose control over a specialty-pharmacy network (Philidor), along with pricing and prescription-handling practices, issues that became central to investor claims. For attorneys, similar structures warrant early disclosure mapping and board-level oversight to reduce misstatement risk.
Restatements and Internal-Control Weaknesses as Litigation Anchors
Valeant acknowledged that financial statements for 2014 and the first three quarters of 2015 were incorrect due to Philidor-related accounting and disclosed material weaknesses in internal controls. Counsel should anticipate how such admissions can frame pleading theories and damages narratives and prepare a response plan around documentation and remedial steps.
Class Strategy, Opt-Outs, and American Pipe Tolling
In Aly v. Valeant (3d Cir. June 16, 2021), the court applied American Pipe tolling to investors who filed individual actions before a class-certification ruling, shaping timing strategy for parallel filings. Attorneys should weigh class participation against individualized suits with a precise calendar anchored to tolling rules.
Settlement Architecture and Special Master Oversight
This case resolved through a $1.21 billion settlement (stipulation dated Dec. 15, 2019; announced Dec. 16, 2019) with final approval on Jan. 31, 2021, after referral to Special Master Hon. Dennis M. Cavanaugh, U.S.D.J. (Ret.). The record underscores how neutral oversight can streamline negotiations and support approval-ready documentation.
Offering Documents and Underwriter Due-Diligence Exposure
Securities Act claims tied to Valeant’s March 2015 offering and the inclusion of underwriter defendants highlight diligence duties for registration statements and prospectuses. For issuers, underwriting syndicates, and counsel, aligning offering disclosures with underlying business practices is a core risk-management task.
The Valeant (now Bausch Health) litigation underscores how undisclosed business arrangements, aggressive pricing practices, and financial restatements can trigger years of high-stakes investor disputes. Spanning from its 2015 public scrutiny to a $1.21 billion class settlement approved in 2021, the case illustrates how corrective disclosures, restated financials, and oversight gaps can reshape both corporate reputation and investor confidence. The resolution, achieved with Special Master oversight, also demonstrates the scale of settlements that can emerge when allegations of misleading disclosures converge with market-wide losses.
At a broader level, this litigation remains a significant reference point in the field of securities litigation, offering insights into disclosure duties, class action strategy, and the role of appellate guidance on tolling doctrines. Attorneys, companies, and investors alike can draw lessons from how the Third Circuit’s Aly v. Valeant ruling influenced opt-out rights, how underwriter defendants were scrutinized under the Securities Act, and how economic damages analyses shaped settlement negotiations. Taken together, the case reinforces the need for rigorous compliance, careful risk disclosure, and strategic planning when navigating complex securities disputes.
What was the class period in the Valeant securities litigation?
The certified class period covered investors who purchased Valeant securities between January 4, 2013, and March 15, 2016. This time frame reflects when the alleged misstatements and omissions occurred.
Why was Valeant sued by investors?
Investors alleged that Valeant misled the market by failing to disclose its control of specialty pharmacy Philidor, using aggressive drug-pricing practices, and recognizing revenue improperly. These issues later led to restated financials and internal-control disclosures.
How much was the Valeant securities litigation settlement?
The litigation resulted in a $1.21 billion settlement, announced in December 2019 and granted final approval in January 2021. The class settlement totaled $1.21 billion and received final approval in January 2021.
Did Valeant admit wrongdoing in the settlement?
Valeant, now Bausch Health Companies Inc., admitted no liability and denied all allegations of wrongdoing. The settlement resolved the class claims while allowing several opt-out suits to proceed separately.
What role did the Third Circuit’s Aly v. Valeant decision play?
The Third Circuit held that American Pipe tolling applied to investors who filed individual actions before a class-certification ruling. This clarified important timing rules for investors considering opt-out litigation.
Why is the Valeant case important for securities litigation?
The case illustrates the risks of undisclosed business practices, the impact of restated financials, and the procedural complexities of large investor class actions. It remains a benchmark for attorneys studying disclosure obligations and settlement strategies in securities litigation.
Securities Litigation Expert Witness
Securities litigation experts are often engaged to analyze alleged market misstatements, explain reliance, and link corrective disclosures to investor losses in securities class actions. In these cases, testimony typically addresses stock-price impact and class-wide damages during the alleged class period. They are generally called in to clarify how disclosures and omissions shaped investor harm.
Accounting Expert Witness
Accounting expert witnesses are often engaged to review financial statements, evaluate GAAP compliance, and assess internal-control disclosures in securities cases. These experts are generally called in to clarify accounting practices, audit responsibilities, and how reporting issues affected investors.
Corporate Governance Expert Witness
Corporate governance experts are often consulted to assess directors’ and officers’ oversight duties, especially when registration statements and public filings are at issue. The Valeant case included allegations involving director sign-offs on the March 2015 stock offering and oversight of disclosure practices. These experts are generally called in to clarify board responsibilities in maintaining accurate corporate reporting.
Economic Damages Expert Witness
Economic Damages experts are often engaged to conduct event studies, measure stock-price inflation, and calculate investor losses tied to corrective disclosures. In such cases, stock value fell dramatically following revelations about Philidor, drug pricing, and restatements, culminating in a $1.21 billion settlement. These experts are generally called in to provide models linking disclosure events to class-wide damages.
Underwriting Expert Witness
Underwriting experts are often engaged to explain securities offering standards, due-diligence practices, and the responsibilities of banks in preparing registration statements. These experts are generally called in to describe industry practices for evaluating disclosures and compliance with federal securities laws.
Disclosure Controls for Complex Distribution Models
The consolidated complaint alleges Valeant failed to transparently disclose control over a specialty-pharmacy network (Philidor), along with pricing and prescription-handling practices, issues that became central to investor claims. For attorneys, similar structures warrant early disclosure mapping and board-level oversight to reduce misstatement risk.
Restatements and Internal-Control Weaknesses as Litigation Anchors
Valeant acknowledged that financial statements for 2014 and the first three quarters of 2015 were incorrect due to Philidor-related accounting and disclosed material weaknesses in internal controls. Counsel should anticipate how such admissions can frame pleading theories and damages narratives and prepare a response plan around documentation and remedial steps.
Class Strategy, Opt-Outs, and American Pipe Tolling
In Aly v. Valeant (3d Cir. June 16, 2021), the court applied American Pipe tolling to investors who filed individual actions before a class-certification ruling, shaping timing strategy for parallel filings. Attorneys should weigh class participation against individualized suits with a precise calendar anchored to tolling rules.
Settlement Architecture and Special Master Oversight
This case resolved through a $1.21 billion settlement (stipulation dated Dec. 15, 2019; announced Dec. 16, 2019) with final approval on Jan. 31, 2021, after referral to Special Master Hon. Dennis M. Cavanaugh, U.S.D.J. (Ret.). The record underscores how neutral oversight can streamline negotiations and support approval-ready documentation.
Offering Documents and Underwriter Due-Diligence Exposure
Securities Act claims tied to Valeant’s March 2015 offering and the inclusion of underwriter defendants highlight diligence duties for registration statements and prospectuses. For issuers, underwriting syndicates, and counsel, aligning offering disclosures with underlying business practices is a core risk-management task.
The Valeant (now Bausch Health) litigation underscores how undisclosed business arrangements, aggressive pricing practices, and financial restatements can trigger years of high-stakes investor disputes. Spanning from its 2015 public scrutiny to a $1.21 billion class settlement approved in 2021, the case illustrates how corrective disclosures, restated financials, and oversight gaps can reshape both corporate reputation and investor confidence. The resolution, achieved with Special Master oversight, also demonstrates the scale of settlements that can emerge when allegations of misleading disclosures converge with market-wide losses.
At a broader level, this litigation remains a significant reference point in the field of securities litigation, offering insights into disclosure duties, class action strategy, and the role of appellate guidance on tolling doctrines. Attorneys, companies, and investors alike can draw lessons from how the Third Circuit’s Aly v. Valeant ruling influenced opt-out rights, how underwriter defendants were scrutinized under the Securities Act, and how economic damages analyses shaped settlement negotiations. Taken together, the case reinforces the need for rigorous compliance, careful risk disclosure, and strategic planning when navigating complex securities disputes.
What was the class period in the Valeant securities litigation?
The certified class period covered investors who purchased Valeant securities between January 4, 2013, and March 15, 2016. This time frame reflects when the alleged misstatements and omissions occurred.
Why was Valeant sued by investors?
Investors alleged that Valeant misled the market by failing to disclose its control of specialty pharmacy Philidor, using aggressive drug-pricing practices, and recognizing revenue improperly. These issues later led to restated financials and internal-control disclosures.
How much was the Valeant securities litigation settlement?
The litigation resulted in a $1.21 billion settlement, announced in December 2019 and granted final approval in January 2021. The class settlement totaled $1.21 billion and received final approval in January 2021.
Did Valeant admit wrongdoing in the settlement?
Valeant, now Bausch Health Companies Inc., admitted no liability and denied all allegations of wrongdoing. The settlement resolved the class claims while allowing several opt-out suits to proceed separately.
What role did the Third Circuit’s Aly v. Valeant decision play?
The Third Circuit held that American Pipe tolling applied to investors who filed individual actions before a class-certification ruling. This clarified important timing rules for investors considering opt-out litigation.
Why is the Valeant case important for securities litigation?
The case illustrates the risks of undisclosed business practices, the impact of restated financials, and the procedural complexities of large investor class actions. It remains a benchmark for attorneys studying disclosure obligations and settlement strategies in securities litigation.
Securities Litigation
Securities Class Action
Securities Fraud
Accounting Fraud
Financial Reporting
Internal Controls
Underwriting
Investment Fraud
Generally Accepted Accounting Principles GAAP
Pharmaceutical, +4
Pharmaceutical
Securities, +4
Pharmaceutical